| Title |
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, November 2011
|
| DOI | 10.1007/s10549-011-1843-1 |
| Pubmed ID | |
| Authors |
Aditya Bardia, Erin T. Arieas, Zhe Zhang, Andrew DeFilippis, Karineh Tarpinian, Stacie Jeter, Anne Nguyen, N. Lynn Henry, David A. Flockhart, Daniel F. Hayes, Jill Hayden, Anna Maria Storniolo, Deborah K. Armstrong, Nancy E. Davidson, John Fetting, Pamela Ouyang, Antonio C. Wolff, Roger S. Blumenthal, M. Dominique Ashen, Vered Stearns |
| Abstract |
The majority of breast cancers are diagnosed in postmenopausal women. Competing comorbidities, particularly cardiovascular disease (CVD), should be considered when individualizing adjuvant therapies for these women. We compared the 10-year predicted breast cancer recurrence risk with CVD risk among postmenopausal women with hormone receptor-positive (HR+), non-metastatic breast cancer. CVD risk factor data were prospectively collected from postmenopausal women with stage I-III, HR+ breast cancer initiating adjuvant aromatase inhibitor therapy. We compared predicted 10-year CVD risk, including the composite index heart age, computed from modified Framingham risk score, with predicted 10-year risk of breast cancer recurrence using Adjuvant! Online. We created multivariable logistic regression models to estimate the odds ratios (OR) and 95% confidence intervals (CI) for greater CVD risk than breast cancer recurrence risk. Among 415 women, mean age and heart age were 60 and 67 years, respectively. Overall, 43% of women had a predicted 10-year CVD risk equivalent to breast cancer recurrence risk and 37% had CVD risk higher than breast cancer recurrence risk. Predicted CVD risk was higher than breast cancer recurrence risk for stage I disease (OR: 6.1, 95% CI: 3.4-11.2) or heart age >65 (OR: 12.4, 95% CI: 7.0-22.6). The majority of postmenopausal women with HR+ early breast cancer had a predicted 10-year CVD risk that was equivalent to or higher than breast cancer recurrence risk. Physicians should weigh competing risks and offer early screening and cardiac prevention strategies for women at a greater risk for CVD. |
Mendeley readers
The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 93 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 17 | 18% |
| Student > Master | 13 | 14% |
| Student > Bachelor | 11 | 12% |
| Student > Ph. D. Student | 9 | 10% |
| Student > Doctoral Student | 6 | 6% |
| Other | 19 | 20% |
| Unknown | 19 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 37 | 39% |
| Nursing and Health Professions | 14 | 15% |
| Psychology | 5 | 5% |
| Agricultural and Biological Sciences | 3 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 8 | 9% |
| Unknown | 25 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 July 2017.
All research outputs
#4,142,796
of 22,656,971 outputs
Outputs from Breast Cancer Research and Treatment
#735
of 4,612 outputs
Outputs of similar age
#24,284
of 141,726 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#7
of 48 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,612 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 141,726 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.